Handelsbanken Fonder Ab Apellis Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 27,600 shares of APLS stock, worth $800,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,600
Previous 23,900
15.48%
Holding current value
$800,676
Previous $917,000
13.2%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
112MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$452 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$345 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$322 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$285 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$168 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.19B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...